Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "pen"

2888 News Found

Aerogen opens India HQ in New Delhi
News | March 20, 2025

Aerogen opens India HQ in New Delhi

The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India


Croda opens advanced lipids manufacturing facility in Pennsylvania
News | March 19, 2025

Croda opens advanced lipids manufacturing facility in Pennsylvania

This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’


Morepen launches Empamore for diabetes care with affordable treatment
News | March 18, 2025

Morepen launches Empamore for diabetes care with affordable treatment

Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health


Amgen opens new technology and innovation site in Hyderabad
Digitisation | February 25, 2025

Amgen opens new technology and innovation site in Hyderabad

Amgen India investment totals $200 million through 2025


ALPLA opens new manufacturing plant in Thailand
Packaging | February 17, 2025

ALPLA opens new manufacturing plant in Thailand

ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies


GSK’s Penmenvy approved by FDA to help protect against MenABCWY
News | February 17, 2025

GSK’s Penmenvy approved by FDA to help protect against MenABCWY

Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)


NATCO, Lupin receive ANDA approval for Bosentan tablets for oral suspension
Drug Approval | February 10, 2025

NATCO, Lupin receive ANDA approval for Bosentan tablets for oral suspension

TFOS is indicated for the treatment of pulmonary arterial hypertension


NATCO announces approval of its ANDA for Everolimus tablets for Oral Suspension
Drug Approval | January 31, 2025

NATCO announces approval of its ANDA for Everolimus tablets for Oral Suspension

Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma